Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Free Cash Flow (2018 - 2025)

Serina Therapeutics (SER) has disclosed Free Cash Flow for 8 consecutive years, with -$6.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 32.3% to -$6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$18.1 million through Dec 2025, down 5.25% year-over-year, with the annual reading at -$18.1 million for FY2025, 5.25% down from the prior year.
  • Free Cash Flow hit -$6.1 million in Q4 2025 for Serina Therapeutics, down from -$3.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $51000.0 in Q4 2023 to a low of -$8.0 million in Q2 2024.
  • Historically, Free Cash Flow has averaged -$2.6 million across 5 years, with a median of -$1.7 million in 2021.
  • Biggest five-year swings in Free Cash Flow: soared 103.86% in 2023 and later tumbled 9107.84% in 2024.
  • Year by year, Free Cash Flow stood at -$1.6 million in 2021, then rose by 19.79% to -$1.3 million in 2022, then skyrocketed by 103.86% to $51000.0 in 2023, then crashed by 9107.84% to -$4.6 million in 2024, then crashed by 32.3% to -$6.1 million in 2025.
  • Business Quant data shows Free Cash Flow for SER at -$6.1 million in Q4 2025, -$3.8 million in Q3 2025, and -$3.8 million in Q2 2025.